Trial Profile
Phase I Study Combining PembRolIzuMab and Hypofractionated Stereotactic Radiotherapy In Patients With Metastatic Non-small-cell lunG Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Dec 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PRIMING
- 18 Dec 2017 New trial record